Chester County News and Community Website
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) unveiled promising results from its Open-Label Extension (OLE) study evaluating ZYN002, a potential treatment for Fragile X syndrome (FXS). The …
Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced the addition of Ron Philip, President and CEO of Orbital Therapeutics, to its Board of Directors. Philip brings …
Harmony Biosciences Appoints Ron Philip to Board of Directors Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced that its management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. …
Harmony Biosciences to Present at 24th Annual Needham Virtual Healthcare Conference Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced the appointment of Adam Zaeske as its new Executive Vice President and Chief Commercial Officer (CCO), effective March 31, …
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced its participation in two upcoming investor conferences.
Harmony Biosciences to Present at Upcoming Global Healthcare Conferences Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced record-breaking financial results for 2024, driven by robust sales of their flagship product WAKIX® (pitolisant). The company reported $714.7 …
Harmony Biosciences Reports Record 2024 Revenue, Targets Billion-Dollar Milestone in 2025 Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File (RTF) letter for its supplemental …
Harmony Biosciences Faces Regulatory Setback, Outlines Future Plans for Pitolisant Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced robust preliminary net product revenues for the fourth quarter and full year of 2024, with figures reaching $201 million …
Harmony Biosciences Reports Strong Revenue Growth and Outlines Ambitious 2025 Strategy Read More
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced a remarkable achievement with $186.0 million in net revenue for the third quarter ending September 30, 2024. This milestone …
Harmony Biosciences Reports Record Revenue and Plans Expansion in CNS Treatments Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is set to showcase its promising late-stage pipeline during an Investor Day event scheduled for October 1 in New York City. …
Harmony Biosciences to Unveil Promising Late-Stage Pipeline at Investor Day Read More